NfL is a cytoskeletal protein reflecting neuroaxonal damage and has emerged as a promising biomarker across a variety of neurological disorders, including MS, ALS, and traumatic brain injury (TBI) [17,18,19]. This evidence concerns the gene NEFL and myeloid sarcoma.